Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Leander

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Pharmaceutical Sciences|July 3, 2014
Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acidSofia Tapani, Joachim Almquist, Jacob Leander, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 6, 2020
Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor ModulatorJoachim Almquist, Muhammad Waqas Sadiq, Ulf G Eriksson, et al.
Communications Medicine|July 31, 2025
A machine learning approach to population pharmacokinetic modelling automationSam Richardson, Itziar Irurzun Arana, Andrzej Nowojewski, et al.
British Journal of Clinical Pharmacology|July 6, 2026
Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthmaAnna Lundahl, Jonathan Grigg, Lubna Abuqayyas, et al.
Respiratory Research|April 14, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)Tania Hugo, Andrew R Harper, Jacob Leander, et al.
The Lancet. Rheumatology|January 23, 2024
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trialsTove Hegelund Myrbäck, Susanne Prothon, Karl Edman, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Pharmaceutical Sciences|July 3, 2014
Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acidSofia Tapani, Joachim Almquist, Jacob Leander, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 6, 2020
Estimation of Equipotent Doses for Anti-Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor ModulatorJoachim Almquist, Muhammad Waqas Sadiq, Ulf G Eriksson, et al.
Communications Medicine|July 31, 2025
A machine learning approach to population pharmacokinetic modelling automationSam Richardson, Itziar Irurzun Arana, Andrzej Nowojewski, et al.
British Journal of Clinical Pharmacology|July 6, 2026
Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthmaAnna Lundahl, Jonathan Grigg, Lubna Abuqayyas, et al.
Respiratory Research|April 14, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)Tania Hugo, Andrew R Harper, Jacob Leander, et al.
The Lancet. Rheumatology|January 23, 2024
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trialsTove Hegelund Myrbäck, Susanne Prothon, Karl Edman, et al.
Mabs|April 15, 2026
Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritisGary P Sims, Lacie Scaletta, John Andrews, et al.
Pageof 2